Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.60 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548026 | 0.94 | L3MBTL1 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL4548016 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL8972364 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL8972105 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL8972071 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL31632756 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL8972852 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL3339374 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL8972731 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A | |
| SCHEMBL8973186 | 0.92 | GNAI3 (0.71) | L3MBTL1GNAI3GNAI1GNAO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-116375715-B | Compound serving as non-covalent BTK kinase inhibitor and biological application thereof | 中国药科大学 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4395549-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | Oerth Bio LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023034411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-3728235-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20130281664-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-10-24 | — | — | US | disclosed |
| US-20130190284-A1 | X-Ray and Gamma-Photon Activable Organic Compounds, Their Preparation and Their Uses | UNIVERSITE RENE PARIS DESCARTES (FR) | 2013-07-25 | — | — | US | disclosed |
| WO-2013060860-A1 | N-ACYL-N'-PHENYLPIPERAZINE DERIVATIVES AS SRBP MODULATORS FOR USE IN THE TREATMENT OF DIABETES AND OBESITY | NATIONAL UNIVERSITY OF IRELAND, MAYNOOTH (IE) | 2013-05-02 | — | — | WO | disclosed |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-10-04 | — | — | US | disclosed |
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-10-04 | — | — | US | disclosed |
| WO-2012052996-A2 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012040204-A2 | CYTOSOLIC FLUORESCENT ION INDICATORS | ASANTE RESEARCH, LLC (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| US-7560480-B2 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-7560480-B2 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253042-A1 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES | ADH5, ADH1C, ADH1A | L3MBTL1 4516/4885GNAI3 4150/4885GNAI1 4158/4885 |
| US-20130190284-A1 | X-Ray and Gamma-Photon Activable Organic Compounds, Their Preparation and Their Uses | GLA, CGAS, VIP | L3MBTL1 4320/4885GNAI3 218/4885GNAI1 177/4885 |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | CRBN, LTN1, CBL | L3MBTL1 157/4885GNAI3 3353/4885GNAI1 3222/4885 |
| US-20130281664-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | ADH5, ADH1C, ADH1A | L3MBTL1 4198/4885GNAI3 4353/4885GNAI1 4462/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | L3MBTL1 191/4885GNAI3 2003/4885GNAI1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.